<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">VMJ</journal-id>
<journal-id journal-id-type="hwp">spvmj</journal-id>
<journal-id journal-id-type="nlm-ta">Vasc Med</journal-id>
<journal-title>Vascular Medicine</journal-title>
<issn pub-type="ppub">1358-863X</issn>
<issn pub-type="epub">1477-0377</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1358863X11424933</article-id>
<article-id pub-id-type="publisher-id">10.1177_1358863X11424933</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Images in vascular medicine</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Penile ischemic lesions associated with anti-phospholipid antibody syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Weinberg</surname><given-names>Ido</given-names></name>
<xref ref-type="aff" rid="aff1-1358863X11424933">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jaff</surname><given-names>Michael R</given-names></name>
<xref ref-type="aff" rid="aff2-1358863X11424933">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1358863X11424933"><label>1</label>Vascular Medicine Section, Cardiology Division, Massachusetts General Hospital, Boston, MA, USA</aff>
<aff id="aff2-1358863X11424933"><label>2</label>Vascular Medicine Section, Cardiology Division, The Vascular Center, Massachusetts General Hospital, Boston, MA, USA</aff>
<author-notes>
<corresp id="corresp1-1358863X11424933">Ido Weinberg, Vascular Medicine Section Cardiology Division Massachusetts General Hospital 55 Fruit St Boston, MA 02114 USA Email: <email>iweinberg@partners.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>17</volume>
<issue>1</issue>
<fpage>68</fpage>
<lpage>69</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>A 70-year-old man presented with fever, rigors, altered mental status and inguinal rash. Past medical history consisted of diabetes mellitus, hypertension, end-stage renal disease and prior ischemic stroke associated with anti-phospholipid antibody syndrome (APLAS) 1 year prior. Since his stroke, he was known to have cognitive impairment. He had been treated with warfarin, which he had stopped 2 months prior to admission following a fall. Physical examination revealed blood pressure of 155/76 mmHg, left shoulder petechiae and a painful, purple rash on the penis (<xref ref-type="fig" rid="fig1-1358863X11424933">Panel A</xref>). Magnetic resonance imaging of the brain was consistent with his age and a previous stroke. Computed tomography of the chest revealed bilateral basilar consolidations. Titers of IgG anticardiolipin were 83.2 g/l (previously &gt; 150 g/l). Lupus anticoagulant and β2-glycoprotein were negative. Biopsy of the penile lesions revealed thrombotic vasculopathy manifesting with occlusion of blood vessels by necrotic material (<xref ref-type="fig" rid="fig2-1358863X11424933">Panel B</xref>; arrows). This was attributed to APLAS. Treatment with IV antibiotics, parenteral anticoagulation and corticosteroids was initiated. No new lesions developed and his condition improved over the course of several weeks.</p>
<fig id="fig1-1358863X11424933" position="float">
<label>Panel A</label>
<graphic xlink:href="10.1177_1358863X11424933-fig1.tif"/>
</fig>
<fig id="fig2-1358863X11424933" position="float">
<label>Panel B</label>
<graphic xlink:href="10.1177_1358863X11424933-fig2.tif"/>
</fig>
<p>APLAS is diagnosed by a combination of characteristic clinical features and elevated antiphospholipid antibodies (APLA) present on at least two occasions, at least 12 weeks apart.<sup><xref ref-type="bibr" rid="bibr1-1358863X11424933">1</xref>,<xref ref-type="bibr" rid="bibr2-1358863X11424933">2</xref></sup> Antibodies can be of one or more of the following types: lupus anticoagulants, anticardiolipin IgG and/or IgM in medium or high titers or anti-β2 glycoprotein-I IgG and/or IgM in levels &gt; 99th percentile.<sup><xref ref-type="bibr" rid="bibr2-1358863X11424933">2</xref></sup> This syndrome causes venous, arterial, and small-vessel thrombosis and pregnancy morbidity. It may also manifest as cardiac valvular disease, renal thrombotic microangiopathy, hemolytic anemia, thrombocytopenia, and cognitive impairment.<sup><xref ref-type="bibr" rid="bibr3-1358863X11424933">3</xref></sup> Cutaneous manifestations of APLAS include livedo reticularis, skin ulcerations and rarely widespread cutaneous necrosis.<sup><xref ref-type="bibr" rid="bibr4-1358863X11424933">4</xref></sup> While penile ischemia with full recovery has been described in patients with APLAS,<sup><xref ref-type="bibr" rid="bibr5-1358863X11424933">5</xref></sup> this is a rare complication. It should be identified promptly as it can offer a diagnostic clue to the syndrome and direct treatment.</p>
<boxed-text id="boxed-text1-1358863X11424933">
<p>‘Images in vascular medicine’ is a regular feature of <italic>Vascular Medicine</italic>. Readers may submit original, unpublished images related to clinical vascular medicine. Submissions may be sent to: Mark A Creager, Editor in Chief, <italic>Vascular Medicine</italic>, via the web-based submission system at <ext-link ext-link-type="uri" xlink:href="http://mc.manuscriptcentral.com/vascular-medicine">http://mc.manuscriptcentral.com/vascular-medicine</ext-link></p>
</boxed-text>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
<fn fn-type="conflict">
<p>Dr. Weinberg has no conflicts of interests to declare. Dr. Jaff is a Member, Board of Trustees, VIVA Physicians, Inc, a 501(c) 3 not for profit physician education and research organization.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1358863X11424933">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>DA</given-names></name>
<name><surname>Khamashta</surname><given-names>MA</given-names></name>
<name><surname>Crowther</surname><given-names>MA.</given-names></name>
</person-group> <article-title>How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review</article-title>. <source>Blood</source> <year>2007</year>; <volume>110</volume>: <fpage>3122</fpage>–<lpage>3127</lpage>.</citation>
</ref>
<ref id="bibr2-1358863X11424933">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miyakis</surname><given-names>S</given-names></name>
<name><surname>Lockshin</surname><given-names>MD</given-names></name>
<name><surname>Atsumi</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>International consensus statement on the update of the classification criteria for definite antiphospholipid syndrome (APS)</article-title>. <source>J Thromb Haemost</source> <year>2006</year>; <volume>4</volume>: <fpage>295</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr3-1358863X11424933">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name>
<name><surname>Crowther</surname><given-names>M</given-names></name>
<name><surname>Branch</surname><given-names>W</given-names></name>
<name><surname>Khamashta</surname><given-names>MA.</given-names></name>
</person-group> <article-title>Antiphospholipid syndrome</article-title>. <source>Lancet</source> <year>2010</year>; <volume>376</volume>: <fpage>1498</fpage>–<lpage>1509</lpage>.</citation>
</ref>
<ref id="bibr4-1358863X11424933">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frances</surname><given-names>S</given-names></name>
</person-group>. <article-title>Dermatological manifestations of Hughes’ antiphospholipid antibody syndrome</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>1071</fpage>–<lpage>1077</lpage>.</citation>
</ref>
<ref id="bibr5-1358863X11424933">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Erkan</surname><given-names>D</given-names></name>
<name><surname>Asherson</surname><given-names>RA</given-names></name>
<name><surname>Espinosa</surname><given-names>G</given-names></name>
<etal/>
</person-group>.; <article-title>Catastrophic Antiphospholipid Syndrome Registry Project Group. Long term outcome of catastrophic antiphospholipid syndrome survivors</article-title>. <source>Ann Rheum Dis</source> <year>2003</year>; <volume>62</volume>: <fpage>530</fpage>–<lpage>533</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>